Spyre Therapeutics Future Growth

Future criteria checks 0/6

Spyre Therapeutics's earnings are forecast to decline at 18.8% per annum while its annual revenue is expected to grow at 81.6% per year. EPS is expected to decline by 14% per annum. Return on equity is forecast to be -201.4% in 3 years.

Key information

-18.8%

Earnings growth rate

-14.04%

EPS growth rate

Biotechs earnings growth	29.0%
Revenue growth rate	81.6%
Future return on equity	-201.41%
Analyst coverage	Good
Last updated	08 Sep 2026

Recent future growth updates

Recent updates

Seeking Alpha • Aug 27

Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade)

Summary In the SKYLINE-UC trial, SPY001 shows competitive endoscopic improvement versus Entyvio, albeit on cross-trial comparison. Initial SKYWAY data with SPY072 in rheumatoid arthritis disappointed, raising doubts about SPY072's potential in other rheumatic indications. SYRE has $1.15B in cash, cash equivalents, and investments, with multiple clinical readouts near-term. Read the full article on Seeking Alpha

Seeking Alpha • Mar 04

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Summary Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis. Upcoming clinical trials in 2025 and 2026 are critical for validating Spyre's therapies and determining its potential to shift the treatment paradigm. Read the full article on Seeking Alpha

Seeking Alpha • Dec 12

Spyre Therapeutics: Different Name, Same Tune

Summary Today, we take an in-depth look at Spyre Therapeutics, Inc., which has promising assets in early-stage development, including SPY001, SPY002, and SPY003. The company changed its name from Aeglea BioTherapeutics, Inc. late last year, and thanks to a recent capital raise, is extremely well funded. Analyst firms also appear optimistic around the company's developmental approach. An analysis of SYRE stock follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Oct 01

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Summary Spyre Therapeutics, Inc. interim data from the phase 1 study, using SPY001 in healthy volunteers, is expected by the end of 2024. SPY001 is an a4b7 inhibitor being developed to target IBD like Crohn's Disease and Ulcerative Colitis. The Crohn's Disease treatment market is projected to reach a value of $17.80 billion by 2033. The global Ulcerative Colitis market is expected to be $10.79 billion by 2030. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:SYRE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	N/A	-402	-341	-333	8
12/31/2027	N/A	-336	-315	-277	11
12/31/2026	N/A	-260	-197	-215	11
6/30/2026	N/A	-150	-139	-209	N/A
3/31/2026	N/A	-149	-149	-186	N/A
12/31/2025	N/A	-127	-162	-169	N/A
9/30/2025	N/A	-118	-155	-162	N/A
6/30/2025	N/A	-163	-147	-154	N/A
3/31/2025	N/A	-159	-170	-170	N/A
12/31/2024	N/A	-150	-157	-157	N/A
9/30/2024	N/A	75	-151	-151	N/A
6/30/2024	N/A	88	-141	-156	N/A
3/31/2024	1	-103	-96	-111	N/A
12/31/2023	1	-95	-85	-100	N/A
9/30/2023	1	-294	-72	-87	N/A
6/30/2023	1	-273	-67	-67	N/A
3/31/2023	1	-78	-72	-72	N/A
12/31/2022	2	-84	-80	-80	N/A
9/30/2022	6	-85	-81	-81	N/A
6/30/2022	7	-88	-83	-83	N/A
3/31/2022	20	-72	-61	-60	N/A
12/31/2021	19	-66	-54	-54	N/A
9/30/2021	15	-68	-53	-52	N/A
6/30/2021	14	-66	-54	-52	N/A
3/31/2021	N/A	-80	-77	-74	N/A
12/31/2020	N/A	-81	-80	-76	N/A
9/30/2020	N/A	-80	-79	-75	N/A
6/30/2020	N/A	-83	-79	-75	N/A
3/31/2020	N/A	-80	N/A	-72	N/A
12/31/2019	N/A	-78	N/A	-66	N/A
9/30/2019	N/A	-72	N/A	-57	N/A
6/30/2019	N/A	-62	N/A	-48	N/A
3/31/2019	2	-53	N/A	-41	N/A
12/31/2018	4	-44	N/A	-32	N/A
9/30/2018	5	-36	N/A	-31	N/A
6/30/2018	7	-32	N/A	-30	N/A
3/31/2018	6	-29	N/A	-27	N/A
12/31/2017	5	-27	N/A	-25	N/A
9/30/2017	5	-26	N/A	-23	N/A
6/30/2017	5	-25	N/A	-22	N/A
3/31/2017	5	-23	N/A	-20	N/A
12/31/2016	5	-22	N/A	-19	N/A
9/30/2016	5	-20	N/A	-15	N/A
6/30/2016	5	-17	N/A	-13	N/A
3/31/2016	7	-13	N/A	-12	N/A
12/31/2015	6	-12	N/A	-11	N/A
9/30/2015	5	-11	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYRE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SYRE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SYRE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SYRE is forecast to have no revenue next year.

High Growth Revenue: SYRE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SYRE is forecast to be unprofitable in 3 years.

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/14 18:08
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spyre Therapeutics, Inc. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
null null	Baird
Mayur Somaiya	BMO Capital Markets Equity Research

Spyre Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 18% to US$118

Price target increased by 11% to US$67.43

Price target increased by 9.9% to US$64.36

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Recent updates

Spyre Therapeutics Announces Positive 12-Week Induction Data From Part A Of The Phase 2 SKYLINE Trial Of SPY003 For Ulcerative Colitis

Spyre Therapeutics Reports Positive Phase 2 Data for SPY003 in Ulcerative Colitis

Chief Financial Officer recently sold US$1.6m worth of stock

Insider notifies of intention to sell stock

Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade)

Spyre Therapeutics Reveals Significant Phase 2 Data for SPY072 in Rheumatoid Arthritis

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-Study of the Skyway Phase 2 Trial of Spy072

Spyre Therapeutics, Inc. Launches SPY772 Program And Initiates Phase 2 SKYLIGHT Trial In Hidradenitis Suppurativa

Price target increased by 18% to US$118

Spyre Therapeutics Posts Positive Phase 2 Data and Hits Key Trial Enrollment Milestones

Chief Financial Officer notifies of intention to sell stock

Spyre Therapeutics, Inc.(NasdaqGS:SYRE) dropped from Russell 2000 Value Benchmark

Spyre Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Chief Financial Officer notifies of intention to sell stock

Insider Divestment of $400 Million Sparks Governance Questions at Spyre Therapeutics

New minor risk - Share price stability

Spyre Shares Rise as SPY002 Shows Positive Phase 2 Results in Ulcerative Colitis Trial

Spyre Therapeutics, Inc. Announces Positive Initial 12-Week Induction Topline Data from Part A of Phase 2 SKYLINE Trial of SPY002 for Treatment Of Moderately-to-Severely Active Ulcerative Colitis

Spyre Therapeutics Completes Enrollment In SKYWAY Basket Trial Evaluating SPY072 In RA, PsA, And AxSpA

Spyre Therapeutics Sets 2026 Data Readouts and Expands SPY003 License Across Indications

Spyre Therapeutics, Inc. Announces Resignation of Peter Harwin from the Board, Effective Effective May 27, 2026

New minor risk - Share price stability

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $403 million.

Spyre Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 11% to US$67.43

Spyre Therapeutics, Inc., Annual General Meeting, May 27, 2026

Price target increased by 9.9% to US$64.36

Spyre Therapeutics, Inc. Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Third Quarter 2026

CEO & Director notifies of intention to sell stock

Spyre Therapeutics, Inc. Appoints Kate Tansey Chevlen as Chief Commercial Officer

New minor risk - Share price stability

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended Anti-IL-23 Antibody

CEO & Director notifies of intention to sell stock

New major risk - Shareholder dilution

New minor risk - Share price stability

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $275.000003 million.

Spyre Therapeutics, Inc. Doses First Patient in Pioneering Phase 2 SKYway Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

Chief Financial Officer recently sold US$300k worth of stock

High number of new and inexperienced directors

Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics, Inc. Announces Poster Presentations at Digestive Disease Week 2025 Including Up to Eight Months of Follow-Up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics, Inc., Annual General Meeting, May 29, 2025

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of Spy003, Its Novel Half-Life Extended Il-23 Antibody

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Spyre Therapeutics: Different Name, Same Tune

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies

Spyre Therapeutics, Inc. has completed a Follow-on Equity Offering.

Spyre Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Spyre Therapeutics, Inc. Announces Positive Interim Phase 1 Data from its First-In-Human Trial of SPY001

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors

Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors

Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Immedica Pharma signed an agreement to acquire global rights to pegzilarginase from Aeglea BioTherapeutics, Inc from Aeglea BioTherapeutics, Inc. (NasdaqCM:AGLE) for $115 million.

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

High number of new directors

Aeglea BioTherapeutics, Inc. announced that it expects to receive $210.000248 million in funding from a group of investors

New major risk - Share price stability

Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. Announces Executive Changes